Brawn Biotech Ltd (530207)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Brawn Biotech's revenue was ₹6.1 Cr (+4.8% year on year, +207.0% on the previous quarter), and net profit ₹0.2 Cr (-35.7% year on year); the operating margin was 0.8%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹6.1 | +4.8% | +207.0% |
| Operating profit | ₹0.0 | -74.5% | from loss |
| Net profit | ₹0.2 | -35.7% | -73.4% |
| EPS (₹) | 0.52 | -35.0% | -73.1% |
| Operating margin | 0.8% | — | — |
📢 Recent Corporate Announcements
Brawn Biotech reported a significant contraction in its top-line for Q1 FY27, with revenue from operations falling 85.7% YoY to ₹0.83 Cr from ₹5.80 Cr. Despite the sharp revenue decline, the company remained profitable with a net profit of ₹0.16 Cr, though this was down 33.3% from ₹0.24 Cr in the year-ago period. The company has also proposed the appointment of M/s GD S M and Co as new statutory auditors for a five-year term. The results reflect a micro-cap company (₹6 Cr market cap) struggling to maintain its previous scale of operations.
- Revenue from operations plummeted to ₹0.83 Cr in Q1 FY27 from ₹5.80 Cr in Q1 FY26.
- Net profit for the quarter stood at ₹0.16 Cr, a decline from ₹0.24 Cr YoY.
- Basic Earnings Per Share (EPS) decreased to ₹0.52 from ₹0.80 in the corresponding quarter last year.
- Total expenses were drastically reduced to ₹0.81 Cr from ₹5.55 Cr, primarily due to lower purchase of stock-in-trade.
- Board recommended the appointment of M/s GD S M and Co as Statutory Auditors for a 5-year term starting from the upcoming AGM.
Brawn Biotech reported a severe contraction in its financial performance for the quarter ended June 30, 2026. Revenue from operations fell to ₹0.82 Cr, an 85.8% decline from ₹5.80 Cr in the same quarter last year. Net profit followed suit, dropping 83.3% YoY to just ₹0.04 Cr. Additionally, the board has recommended the appointment of M/s G D S M and Co as new statutory auditors for a five-year term, pending shareholder approval at the upcoming AGM on September 29, 2026.
- Revenue from operations declined sharply to ₹0.82 Cr from ₹5.80 Cr in June 2025.
- Net profit for the quarter stood at ₹0.04 Cr, down from ₹0.24 Cr in the year-ago period.
- Total expenses were curtailed to ₹0.86 Cr, down from ₹5.65 Cr YoY, primarily due to lower purchase of stock-in-trade.
- The board recommended a new statutory auditor, M/s G D S M and Co, for a 5-year tenure (2026-2031).
- The 41st Annual General Meeting (AGM) is scheduled for September 29, 2026, via video conferencing.
Brawn Biotech has scheduled a board meeting for August 13, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of just Rs 7 Cr and TTM revenue of Rs 17 Cr. Investors will be looking for a recovery in performance, as quarterly revenue declined significantly from Rs 5.8 Cr in June 2025 to Rs 1.98 Cr in March 2026. The trading window for insiders remains closed until August 15, 2026.
- Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results
- Trading window for insiders closed until August 15, 2026
- Company reported a TTM revenue of Rs 17 Cr against a small market cap of Rs 7 Cr
- Operating margins (TTM) currently stand at -1.9%
- Revenue in the most recent quarter (March 2026) was Rs 1.98 Cr
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
